person · Reporting owner

Collins Helen Louise

Disclosed activity across 4 companies

Tapewire entity: 21637
SEC CIK: 0001701247

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Enliven Therapeutics, Inc.ELVN · Entity 4024	CHIEF MEDICAL OFFICER	September 17, 2026	September 21, 2026
IO Biotech, Inc.IOBT · Entity 8764	Director	June 05, 2025	June 06, 2025
Kura Oncology, Inc.KURA · Entity 4871	Director	June 04, 2026	June 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Enliven Therapeutics, Inc.

Report date September 17, 2026 · Filed September 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,000	Reported balance After 2026-09-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-17 · Exercise / conversion · Acquired 5,000 · Balance 30,000 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Common StockSEC Table I · non-derivative	Direct	27,084	Reported balance After 2026-09-17 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-09-17 · Sale · Disposed 2,916 · Balance 27,084 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3: This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Common StockSEC Table I · non-derivative	Direct	25,240	Reported balance After 2026-09-17 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2026-09-17 · Sale · Disposed 1,844 · Balance 25,240 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F4: This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Common StockSEC Table I · non-derivative	Direct	25,000	Reported balance After 2026-09-17 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2026-09-17 · Sale · Disposed 240 · Balance 25,000 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F6: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2031-06-17	Direct	106,268	Reported balance After 2026-09-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-17 · Exercise / conversion · Disposed 5,000 · Balance 106,268 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F7: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Filing footnotes · ownership attribution and instrument terms

F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.

F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

F3: This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

F7: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

IO Biotech, Inc.

Report date June 05, 2025 · Filed June 06, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-06-05	Direct	35,144	Reported balance After 2025-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-05 · Grant · Acquired 35,144 · Balance 35,144 F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Filing footnotes · ownership attribution and instrument terms

F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Kura Oncology, Inc.

Report date June 04, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03	Direct	35,000	Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests in full on the one year anniversary of the date of grant.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

FIVE PRIME THERAPEUTICS, INC.

Report date March 31, 2021 · Filed April 19, 2021

Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2021-04-16 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2021-03-31 · Gift · Disposed 8,085 · Balance 69,547 Row 2 · 2021-04-16 · Grant · Acquired 66,000 · Balance 135,547 F1: Represents shares of performance-based restricted Common Stock (as defined below) granted to the reporting person on June 24, 2019 (the "Performance Award"). The performance conditions associated with the Performance Award have not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the Performance Award was deemed to have vested and each share of Common Stock underlying the Performance Award was converted into the right to receive the Offer Price (as defined below) in cash, without interest, minus any applicable withholding taxes. Row 3 · 2021-04-16 · Disposition to issuer · Disposed 135,547 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.89	Direct	Reported balance After 2021-04-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-04-16 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.69	Direct	Reported balance After 2021-04-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-04-16 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.97	Direct	Reported balance After 2021-04-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-04-16 · Disposition to issuer · Disposed 58,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78	Direct	Reported balance After 2021-04-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-04-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25	Direct	Reported balance After 2021-04-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-04-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25	Direct	Reported balance After 2021-04-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-04-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of performance-based restricted Common Stock (as defined below) granted to the reporting person on June 24, 2019 (the "Performance Award"). The performance conditions associated with the Performance Award have not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the Performance Award was deemed to have vested and each share of Common Stock underlying the Performance Award was converted into the right to receive the Offer Price (as defined below) in cash, without interest, minus any applicable withholding taxes.

F2: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes.

F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F4: Not applicable.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 17, 2026 Filed Sep 21, 2026 21:22 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000013 · form4-09212026_090903.xml · derivative · entry 5 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,268 Underlying: Common Stock · 5,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F7 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
September 17, 2026 Filed Sep 21, 2026 21:22 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	240	$51.48	$12,355.68	Disclosure SEC source: 0001701247-26-000013 · form4-09212026_090903.xml · nonDerivative · entry 4 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F6 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
September 17, 2026 Filed Sep 21, 2026 21:22 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	1,844	$50.71	$93,507.21	Disclosure SEC source: 0001701247-26-000013 · form4-09212026_090903.xml · nonDerivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,240 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
September 17, 2026 Filed Sep 21, 2026 21:22 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	2,916	$50.03	$145,890.98	Disclosure SEC source: 0001701247-26-000013 · form4-09212026_090903.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,084 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
September 17, 2026 Filed Sep 21, 2026 21:22 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	5,000	$2.48	$12,400.00	Disclosure SEC source: 0001701247-26-000013 · form4-09212026_090903.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:16 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000012 · form4-08192026_080807.xml · derivative · entry 4 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,268 Underlying: Common Stock · 5,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:16 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	1,100	$59.35	$65,281.15	Disclosure SEC source: 0001701247-26-000012 · form4-08192026_080807.xml · nonDerivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $58.985 to $59.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F5 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:16 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	3,900	$58.37	$227,649.63	Disclosure SEC source: 0001701247-26-000012 · form4-08192026_080807.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,100 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $57.895 to $58.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
August 17, 2026 Filed Aug 19, 2026 20:16 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	5,000	$2.48	$12,400.00	Disclosure SEC source: 0001701247-26-000012 · form4-08192026_080807.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
July 17, 2026 Filed Jul 21, 2026 21:23 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000011 · form4-07212026_090758.xml · derivative · entry 7 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,268 Underlying: Common Stock · 5,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F9 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
July 17, 2026 Filed Jul 21, 2026 21:23 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	63	$53.92	$3,397.01	Disclosure SEC source: 0001701247-26-000011 · form4-07212026_090758.xml · nonDerivative · entry 6 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $53.8793 to $53.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F8 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
July 17, 2026 Filed Jul 21, 2026 21:23 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	2,184	$53.42	$116,669.06	Disclosure SEC source: 0001701247-26-000011 · form4-07212026_090758.xml · nonDerivative · entry 5 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,063 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $52.8741 to $53.8708. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
July 17, 2026 Filed Jul 21, 2026 21:23 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	2,063	$52.39	$108,084.90	Disclosure SEC source: 0001701247-26-000011 · form4-07212026_090758.xml · nonDerivative · entry 4 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,247 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $51.8711 to $52.845. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
July 17, 2026 Filed Jul 21, 2026 21:23 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	459	$51.55	$23,659.89	Disclosure SEC source: 0001701247-26-000011 · form4-07212026_090758.xml · nonDerivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,310 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.85 to $51.8305. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
July 17, 2026 Filed Jul 21, 2026 21:23 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	231	$50.05	$11,562.52	Disclosure SEC source: 0001701247-26-000011 · form4-07212026_090758.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,769 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3565. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
July 17, 2026 Filed Jul 21, 2026 21:23 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	5,000	$2.48	$12,400.00	Disclosure SEC source: 0001701247-26-000011 · form4-07212026_090758.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 17, 2026 Filed Jun 22, 2026 21:11 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000010 · form4-06222026_090652.xml · derivative · entry 5 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,268 Underlying: Common Stock · 5,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F7 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
June 17, 2026 Filed Jun 22, 2026 21:11 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	1,133	$44.74	$50,693.82	Disclosure SEC source: 0001701247-26-000010 · form4-06222026_090652.xml · nonDerivative · entry 4 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $44.3005 to $44.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F6 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 17, 2026 Filed Jun 22, 2026 21:11 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	2,599	$43.87	$114,018.39	Disclosure SEC source: 0001701247-26-000010 · form4-06222026_090652.xml · nonDerivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,133 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $43.30 to $44.2925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 17, 2026 Filed Jun 22, 2026 21:11 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	1,268	$42.83	$54,304.64	Disclosure SEC source: 0001701247-26-000010 · form4-06222026_090652.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,732 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.295 to $43.2752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 17, 2026 Filed Jun 22, 2026 21:11 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	5,000	$2.48	$12,400.00	Disclosure SEC source: 0001701247-26-000010 · form4-06222026_090652.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 04, 2026 Filed Jun 4, 2026 22:30 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	35,000	$0.00 Strike: $8.77	$0.00	Disclosure SEC source: 0001193125-26-257900 · ownership.xml · derivative · entry 1 Collins Helen Louise · CIK 0001701247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
May 18, 2026 Filed May 20, 2026 20:18 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000007 · form4-05202026_080544.xml · derivative · entry 5 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,268 Underlying: Common Stock · 5,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F7 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
May 18, 2026 Filed May 20, 2026 20:18 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	223	$41.21	$9,188.76	Disclosure SEC source: 0001701247-26-000007 · form4-05202026_080544.xml · nonDerivative · entry 4 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $40.8625 to $41.605. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F6 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 18, 2026 Filed May 20, 2026 20:18 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	1,302	$40.25	$52,401.98	Disclosure SEC source: 0001701247-26-000007 · form4-05202026_080544.xml · nonDerivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,223 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $39.855 to $40.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 18, 2026 Filed May 20, 2026 20:18 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	3,475	$39.53	$137,380.65	Disclosure SEC source: 0001701247-26-000007 · form4-05202026_080544.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,525 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $38.855 to $39.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 18, 2026 Filed May 20, 2026 20:18 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	5,000	$2.48	$12,400.00	Disclosure SEC source: 0001701247-26-000007 · form4-05202026_080544.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
April 17, 2026 Filed Apr 22, 2026 00:40 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000006 · form4-04222026_120411.xml · derivative · entry 5 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,268 Underlying: Common Stock · 5,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F7 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
April 17, 2026 Filed Apr 22, 2026 00:40 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	2,441	$48.06	$117,303.48	Disclosure SEC source: 0001701247-26-000006 · form4-04222026_120411.xml · nonDerivative · entry 4 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $47.8303 to $48.4936. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F6 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
April 17, 2026 Filed Apr 22, 2026 00:40 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	2,419	$47.39	$114,635.44	Disclosure SEC source: 0001701247-26-000006 · form4-04222026_120411.xml · nonDerivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,441 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $46.8218 to $47.8166. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
April 17, 2026 Filed Apr 22, 2026 00:40 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	140	$45.81	$6,413.50	Disclosure SEC source: 0001701247-26-000006 · form4-04222026_120411.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,860 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.525 to $46.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
April 17, 2026 Filed Apr 22, 2026 00:40 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	5,000	$2.48	$12,400.00	Disclosure SEC source: 0001701247-26-000006 · form4-04222026_120411.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 25, 2026 Filed Mar 27, 2026 20:57 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000005 · form4-03272026_080317.xml · derivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,268 Underlying: Common Stock · 40,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
March 25, 2026 Filed Mar 27, 2026 20:57 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	40,000	$35.10	$1,404,024.00	Disclosure SEC source: 0001701247-26-000005 · form4-03272026_080317.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 25, 2026 Filed Mar 27, 2026 20:57 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	40,000	$2.48	$99,200.00	Disclosure SEC source: 0001701247-26-000005 · form4-03272026_080317.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 17, 2026 Filed Mar 19, 2026 21:50 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000004 · form4-03192026_090347.xml · derivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,268 Underlying: Common Stock · 5,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
March 17, 2026 Filed Mar 19, 2026 21:50 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	5,000	$27.76	$138,800.00	Disclosure SEC source: 0001701247-26-000004 · form4-03192026_090347.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.40 to $28.2278. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 17, 2026 Filed Mar 19, 2026 21:50 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	5,000	$2.48	$12,400.00	Disclosure SEC source: 0001701247-26-000004 · form4-03192026_090347.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 10, 2026 Filed Mar 11, 2026 21:32 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	10,129	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000003 · form4-03112026_090319.xml · derivative · entry 6 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,268 Underlying: Common Stock · 10,129 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
March 10, 2026 Filed Mar 11, 2026 21:32 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	10,129	$30.19	$305,826.92	Disclosure SEC source: 0001701247-26-000003 · form4-03112026_090319.xml · nonDerivative · entry 4 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 10, 2026 Filed Mar 11, 2026 21:32 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	10,129	$2.48	$25,119.92	Disclosure SEC source: 0001701247-26-000003 · form4-03112026_090319.xml · nonDerivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 09, 2026 Filed Mar 11, 2026 21:32 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	29,871	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000003 · form4-03112026_090319.xml · derivative · entry 5 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,397 Underlying: Common Stock · 29,871 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
March 09, 2026 Filed Mar 11, 2026 21:32 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	29,871	$30.02	$896,811.06	Disclosure SEC source: 0001701247-26-000003 · form4-03112026_090319.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 09, 2026 Filed Mar 11, 2026 21:32 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	29,871	$2.48	$74,080.08	Disclosure SEC source: 0001701247-26-000003 · form4-03112026_090319.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
February 17, 2026 Filed Feb 19, 2026 23:36 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001701247-26-000002 · form4-02192026_110242.xml · derivative · entry 3 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,268 Underlying: Common Stock · 45,000 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
February 17, 2026 Filed Feb 19, 2026 23:36 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	SaleCommon Stock	45,000	$26.17	$1,177,861.50	Disclosure SEC source: 0001701247-26-000002 · form4-02192026_110242.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.76 to $26.695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document
February 17, 2026 Filed Feb 19, 2026 23:36 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	Exercise / conversionCommon Stock	45,000	$2.48	$111,600.00	Disclosure SEC source: 0001701247-26-000002 · form4-02192026_110242.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:47 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantStock Option (right to buy) · Derivative	150,000	$0.00 Strike: $27.16	$0.00	Disclosure SEC source: 0001701247-26-000001 · form4-02182026_120250.xml · derivative · entry 2 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-12 F2 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:47 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001701247-26-000001 · form4-02182026_120250.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · balance_after: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 05, 2025 Filed Jun 6, 2025 20:24 UTC	IO Biotech, Inc. IOBT · Entity 8764	GrantStock Option (Right to Buy) · Derivative	35,144	$0.00 Strike: $1.50	$0.00	Disclosure SEC source: 0000905148-25-002029 · form4.xml · derivative · entry 1 Collins Helen Louise · CIK 0001701247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,144 Underlying: Common Stock · 35,144 shares Expires 2035-06-05 F1 · derivative.exercise_date: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.